Anti-Citrullinated Protein Antibodies (ACPA) come in many different flavors. Besides the CCP2-antigen commonly used in diagnostic tests, they can also recognize various other antigens, which determine the so-called antibody fine specificity. Numerous studies have investigated these ACPA fine specificities, but what has this taught us so far? How do ACPA fine specificities contribute to our understanding of RA, and are they of any use to our patients?
This presentation will discuss not only the role of ACPA fine specificities in the pathophysiology of rheumatoid arthritis (RA), but also whether they can be used for diagnostic or prognostic ends. Regarding pathophysiology, the study of ACPA fine specificities has contributed to our understanding of the temporal development of the ACPA response. They have also provided new insights concerning the well-known association between RA and certain HLA alleles. Their role in diagnosis and prognosis of RA appears to be limited at the present time, but this lecture will also provide a glimpse of the future of ACPA fine specificity research and the promises ahead.
Disclosure of Interest None declared